Healthcare Services

Global Monkey Pox Treatment Industry Trends and Market Growth Forecast for 2026–2030

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Monkey Pox Treatment Market Projected To Become By 2030 Based On Its 2026 Valuation?

The monkey pox treatment market has experienced swift expansion recently. It is anticipated to climb from $0.1 billion in 2025 to $0.11 billion by 2026, registering a compound annual growth rate (CAGR) of 13.0%. The market’s historical rise can be attributed to several factors, including earlier outbreaks in regions where the disease is common, restricted access to vaccines, late diagnoses stemming from limited awareness, a reliance on supportive care, and its global dissemination during the 2022 outbreak.

The monkey pox treatment market is projected for significant expansion in the coming years. It is set to reach $0.18 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This growth during the forecast period is fueled by factors such as the expanding antiviral pipeline, increasing global vaccination efforts, greater investment in infectious disease research, the adoption of enhanced diagnostic tools, and developing government preparedness strategies. Key developments anticipated in the forecast period encompass the advancement of precision-based antiviral solutions, the integration of AI-powered models for outbreak forecasting, the proliferation of digital tracking systems for case monitoring, the expanding deployment of IoT-enabled disease surveillance networks, and a heightened demand for sustainable vaccine manufacturing processes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18818&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Monkey Pox Treatment Market?

The escalating occurrence of zoonotic infections is anticipated to boost the monkeypox treatment market’s expansion moving forward. A zoonotic infection is an illness transmitted from animals to humans via direct contact with contaminated environments or vectors. Increased human-animal interaction, bringing individuals and animals into closer proximity, elevates the risks of zoonotic infection. Furthermore, climate change intensifies this risk by broadening disease vector ranges and introducing pathogens into new regions. Monkeypox treatments are utilized to manage zoonotic mpox by targeting the virus and easing symptoms in both humans and potentially affected animals. For instance, according to an August 2024 report by the UK Health Security Agency, a UK-based government agency, there were 3,732 confirmed mpox cases in the UK; it also noted that cases in 2023 reached 3753, representing a rise of 21. Thus, the increasing prevalence of zoonotic infection propels the monkeypox treatment market.

What Segment Groups Are Identified Within The Monkey Pox Treatment Market?

The monkey pox treatment market covered in this report is segmented –

1) By Treatment Type: Prophylactic Vaccines, Therapeutics

2) By Dosage Forms: Solid, Liquid, Semi Solid

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Prophylactic Vaccines: Vaccinia-Based Vaccines, Modified Vaccinia Ankara (MVA) Vaccines

2) By Therapeutics: Antiviral Agents (Tecovirimat, Brincidofovir), Immune Modulators, Supportive Care Treatments

What Trends Are Projected To Affect The Monkey Pox Treatment Market?

Major companies operating in the monkeypox treatment market are prioritizing the development of innovative products, such as small-molecule antivirals, to boost global health preparedness and stockpiling capabilities. Small-molecule antivirals work by inhibiting specific viral proteins to halt virus proliferation within the body and offer long-term storage, making them optimal for emergency situations. For instance, in January 2025, SIGA Technologies, a US-based pharmaceutical company, received approval in Japan for TEPOXX (tecovirimat 200 mg capsules), which is the first antiviral for treating orthopoxviruses in that nation. This product demonstrates a strong safety profile, supported by data from 15 clinical trials involving over 800 healthy volunteers, showed quantifiable pharmacokinetics within effective dose ranges, and exhibited robust preclinical efficacy in animal models where it reduced both mortality and viral load. The drug operates by inhibiting the VP37 protein on the virus surface, preventing viral exit from infected cells, which allows the immune system to clear the infection. SIGA has collaborated with Japan Biotechno Pharma as its sole distributor to create Japan’s strategic national stockpile of TEPOXX.

Which Companies Hold Significant Positions In The Monkey Pox Treatment Market?

Major companies operating in the monkey pox treatment market are Merck & Co Inc, Sanofi S A, Gilead Sciences Inc, BioNTech SE, Moderna Inc, Novavax Inc, Emergent BioSolutions Inc, Bavarian Nordic A S, SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, Chimerix Inc, Emcure Pharmaceuticals Ltd, VBI Vaccines Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, GeoVax Labs Inc, Zydus Cadila Ltd, Serum Institute of India Pvt Ltd, Biological E Ltd, Dr Reddy’s Laboratories Ltd, Hester Bioscience Ltd, Indian Immunologicals Ltd, Reliance Life Sciences Pvt Ltd, Takeda Pharmaceuticals Co Ltd, KM Biologics Co Ltd, Meridian Bioscience Inc, NanoViricides Inc.

Read the full monkey pox treatment market report here:

https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

Which Regions Are Projected To Dominate The Monkey Pox Treatment Market In The Coming Years?

North America was the largest region in the monkey pox treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Monkey Pox Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18818&type=smp

Browse Through More Reports Similar to the Global Monkey Pox Treatment Market 2026, By The Business Research Company

Monkey Pox Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/monkey-pox-treatment-global-market-report

Infectious Disease Diagnostics Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Non Animal Alternatives Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/non-animal-alternatives-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795